Following GlaxoSmithKline's agreement to pay $750 million to settle a fraud lawsuit against the company, federal investigators are now hoping to see if any action can be taken against its executive leaders, according to a New York Times news report.
Although officials have declined to comment on the issue and the GlaxoSmithKline case technically falls outside the five-year statute of limitations for federal misdemeanor prosecutions, the government could pursue prosecution under the Park doctrine. The liability standard allows misdemeanor prosecution of company officials for violating the Food, Drug and Cosmetic Act whether or not the officials knew about the violation, according to the report.
Read the New York Times news report about the Park doctrine.
Read other coverage about pharmaceutical fraud:
- GlaxoSmithKline Will Pay $750M to Settle Medicaid Fraud Lawsuit
- Advocacy Group: Pharmaceutical Companies Top List of DOJ Settlements
- News Database Reveals Financial Relationships Between Physicians and Pharmaceutical Companies
Although officials have declined to comment on the issue and the GlaxoSmithKline case technically falls outside the five-year statute of limitations for federal misdemeanor prosecutions, the government could pursue prosecution under the Park doctrine. The liability standard allows misdemeanor prosecution of company officials for violating the Food, Drug and Cosmetic Act whether or not the officials knew about the violation, according to the report.
Read the New York Times news report about the Park doctrine.
Read other coverage about pharmaceutical fraud:
- GlaxoSmithKline Will Pay $750M to Settle Medicaid Fraud Lawsuit
- Advocacy Group: Pharmaceutical Companies Top List of DOJ Settlements
- News Database Reveals Financial Relationships Between Physicians and Pharmaceutical Companies